THE DUAL ACTIVATOR

Mazdutide

Grade C — Moderate

Next-gen weight loss with dual hormone action

Also known as: OXM3; IBI362; LY3305677

Appetite & Metabolic Control
Weight Management
Anti-Aging & Longevity

Overview

Mazdutide is a dual GLP-1/glucagon receptor agonist being developed for obesity and type 2 diabetes. Unlike single-target drugs like semaglutide, it activates both receptors for potentially greater weight loss. The GLP-1 action reduces appetite and slows digestion, while glucagon activation increases energy expenditure and fat burning. Early trials show impressive results.

Key Benefits & Mechanisms

Appetite Suppression

GLP-1 activation reduces hunger and food intake

Increased Thermogenesis

Glucagon receptor activation boosts energy expenditure

Glucose Control

Improves insulin secretion and blood sugar regulation

Gastric Slowing

Delays stomach emptying for prolonged satiety

Dosing Guide

Dosage

1-6 mg once weekly (subcutaneous injection)

Schedule

weekly

Cycle

Ongoing as prescribed in clinical trials

Pro Tip

Start at low dose and titrate up to minimize GI side effects

This peptide requires titration — start with a lower dose and increase gradually.

Safety Profile

C

Moderate Safety

Moderate

Still in clinical trials. Similar side effect profile to other GLP-1 drugs.

Investigational drug - not yet approved. Use only under clinical supervision.

Possible Side Effects

Nausea
Vomiting
Diarrhea
Injection site reactions
Decreased appetite

What to Expect

Week 1-2

Reduced appetite, possible nausea during adjustment

Week 2-4

Initial weight loss, improved blood sugar

Week 4-12

Significant weight loss, metabolic improvements

Month 3-6

Continued weight loss, potential cardiovascular benefits

Weight loss typically begins in the first 2-4 weeks.

Who Is This For

Those with significant weight to lose
People with type 2 diabetes
Those who haven't responded well to GLP-1 alone
People seeking metabolic reset
Those interested in cutting-edge obesity treatments

Research References

[1]Mazdutide Phase 2 Trial Results - Eli Lilly/Innovent

Related Peptides

CJC-1295 (no DAC)

B

THE GH SUSTAINER

Long-acting growth hormone releaser for muscle, recovery and anti-aging

BAM-15

B

THE CALORIE BURNER

Make your cells burn more fuel - mitochondrial uncoupling for fat loss

Cardiogen

A

THE CARDIAC REGENERATOR

Four-amino-acid peptide for heart repair and regeneration

Chitomur

A

THE BLADDER HEALER

Restore bladder function and urinary comfort

Glandokort

A

THE ADRENAL REJUVENATOR

Restore adrenal function and stress resilience

Gotratix

A

THE MUSCLE REGENERATOR

Muscle peptide for strength, endurance, and recovery

Ready to Start Your Peptide Journey?

Track your protocols, get guided reconstitution, and access our vetted vendor network — all in one app.

Download The Peptide App